These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33253790)

  • 1. Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer.
    Zheng Y; Wang Z; Wei S; Liu Z; Chen G
    Cancer Lett; 2021 Feb; 499():148-163. PubMed ID: 33253790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
    Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
    Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
    Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
    Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
    Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
    Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.
    Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
    Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
    Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
    Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
    Poirier JT; Gardner EE; Connis N; Moreira AL; de Stanchina E; Hann CL; Rudin CM
    Oncogene; 2015 Nov; 34(48):5869-78. PubMed ID: 25746006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
    Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
    Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
    Shi MX; Ding X; Tang L; Cao WJ; Su B; Zhang J
    BMC Cancer; 2024 Apr; 24(1):504. PubMed ID: 38644473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer.
    Wang YF; Yu L; Hu ZL; Fang YF; Shen YY; Song MF; Chen Y
    Cell Death Dis; 2022 Aug; 13(8):748. PubMed ID: 36038549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
    Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
    Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance.
    Zhai G; Li J; Zheng J; An P; Chen X; Wang X; Li C
    J Radiat Res; 2020 Sep; 61(5):674-683. PubMed ID: 32761059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.
    Sato T; Kaneda A; Tsuji S; Isagawa T; Yamamoto S; Fujita T; Yamanaka R; Tanaka Y; Nukiwa T; Marquez VE; Ishikawa Y; Ichinose M; Aburatani H
    Sci Rep; 2013; 3():1911. PubMed ID: 23714854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.
    Liu T; Miao Z; Jiang J; Yuan S; Fang W; Li B; Chen Y
    Int J Mol Sci; 2015 May; 16(5):11439-51. PubMed ID: 25993304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.